These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 14712413)

  • 21. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
    Romanos E; Planas AM; Amaro S; Chamorro A
    J Cereb Blood Flow Metab; 2007 Jan; 27(1):14-20. PubMed ID: 16596120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 25. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
    Okubo S; Igarashi H; Kanamatsu T; Hasegawa D; Orima H; Katayama Y
    Brain Res; 2007 Apr; 1143():221-7. PubMed ID: 17316578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke.
    Thomas GR; Thibodeaux H; Bennett WF; Refino CJ; Badillo JM; Errett CJ; Zivin JA
    J Pharmacol Exp Ther; 1993 Jan; 264(1):67-73. PubMed ID: 8423552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombolytic therapy in experimental embolic stroke.
    Overgaard K
    Cerebrovasc Brain Metab Rev; 1994; 6(3):257-86. PubMed ID: 7811566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Histopathology analysis of microemboli after thrombolysis].
    Zhu HY; Shen H; Liu YY; Zhang W; Zhao XM
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Apr; 18(4):216-8. PubMed ID: 16647011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombolysis in acute ischemic stroke.
    Lang W; Domanovits H; Görzer H; Germann P; Gatterbauer E; Segall B
    Acta Anaesthesiol Scand Suppl; 1997; 111():34-7. PubMed ID: 9420947
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of thrombolysis on the dynamics of infarct evolution after clot embolism of middle cerebral artery in mice.
    Hara T; Mies G; Hossmann KA
    J Cereb Blood Flow Metab; 2000 Oct; 20(10):1483-91. PubMed ID: 11043911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel model for evaluating thrombolytic therapy in dogs with ST-elevation myocardial infarction.
    Zhang H; Cui YC; Tian Y; Yuan WM; Yang JZ; Peng P; Li K; Liu XP; Zhang D; Wu AL; Zhou Z; Tang Y
    BMC Cardiovasc Disord; 2016 Jan; 16():21. PubMed ID: 26811249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
    Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
    Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New method of embolus preparation for standardized embolic stroke in rabbits.
    Kirchhof K; Welzel T; Zoubaa S; Lichy C; Sikinger M; de Ruiz HL; Sartor K
    Stroke; 2002 Sep; 33(9):2329-33. PubMed ID: 12215607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probability of metabolic tissue recovery after thrombolytic treatment of experimental stroke: a magnetic resonance spectroscopic imaging study in rat brain.
    Franke C; Brinker G; Pillekamp F; Hoehn M
    J Cereb Blood Flow Metab; 2000 Mar; 20(3):583-91. PubMed ID: 10724122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolysis 2004: the good, the bad, and the ugly.
    Caplan LR
    Rev Neurol Dis; 2004; 1(1):16-26. PubMed ID: 16397447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
    El Amki M; Lerouet D; Coqueran B; Curis E; Orset C; Vivien D; Plotkine M; Marchand-Leroux C; Margaill I
    Exp Neurol; 2012 Dec; 238(2):138-44. PubMed ID: 22921458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion.
    Hattenbach LO; Kuhli-Hattenbach C; Scharrer I; Baatz H
    Am J Ophthalmol; 2008 Nov; 146(5):700-6. PubMed ID: 18718570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.